A New Stroke Drug with an 'Off-Switch' Shows Promise Against Old Clots

RESEARCH TRIANGLE, N.C. – July 30, 2026 – For decades, the treatment of acute ischemic stroke—the kind caused by a blood clot in the brain—has been a desperate race against a ticking clock. Now, new preclinical data suggests a novel therapeutic approach could not only extend that critical window but also provide an unprecedented safety feature: an "off-switch."

Basking Biosciences, a clinical-stage company, has published compelling findings in the journal Communications Biology for its lead candidate, BB-031. The study, using a sophisticated lab model that mimics arterial blockages with blood from stroke patients, shows the drug can dissolve stubborn, hours-old clots more effectively than the current standard of care. This isn't just an incremental improvement; it's a fundamental shift in strategy that targets the very architecture of the most dangerous blood clots.

A New Mechanism to Tackle Stubborn Clots

Current clot-busting drugs, known as fibrinolytics like alteplase (tPA), work by breaking down fibrin, the protein mesh that forms the bulk of a clot. While effective, their power is indiscriminate, and their use is limited to a narrow 3- to 4.5-hour window after symptoms begin due to a serious risk of brain hemorrhage.

Basking's BB-031 takes a different, more targeted approach. It is an RNA aptamer—a short strand of nucleic acid that folds into a precise shape to bind a specific target—designed to inhibit a protein called von Willebrand Factor (vWF). This protein acts as the foundational glue for arterial clots, initiating their formation and continually recruiting platelets to reinforce the blockage, making it denser and more resistant to treatment over time.

"Von Willebrand Factor continually recruits platelets that reinforce arterial clots, thereby engendering resistance to current therapies," explained Shahid M. Nimjee, M.D., Ph.D., co-founder and chief scientific officer of Basking Biosciences. "By selectively inhibiting vWF, BB-031 stops that reinforcement and allows blood flow to return, even when treatment is administered hours after the occlusion forms."

The new study, led by researchers at the University of Pittsburgh and The Ohio State University, put this theory to the test. In a microfluidic model, they created fully occlusive, platelet-rich clots and allowed them to mature for up to six hours—a scenario that better reflects the clinical reality for many stroke patients. When treated, BB-031 restored blood flow more effectively than both alteplase and tenecteplase, particularly in these aged, more challenging clots.

"The model allowed us to see what may be happening to arterial clots in prolonged settings, providing a closer analog to clinical reality," said Susan M. Shea, M.S.M.E., Ph.D., the study's senior author from the University of Pittsburgh. This validation in a system that reproduces the composition of clots retrieved from actual stroke patients adds significant weight to the findings.

Racing Against the Clock: The Crisis in Stroke Care

The potential impact of this innovation can only be understood against the backdrop of the current crisis in stroke treatment. Acute ischemic stroke accounts for 87% of the 15 million strokes that occur worldwide each year. It is a leading cause of death and long-term disability, yet the vast majority of patients—upwards of 80% even in well-equipped regions—receive no acute intervention to restore blood flow.

The reason is time. The narrow therapeutic window for existing fibrinolytics means most patients arrive at the hospital too late to be eligible. For those who do qualify, the risk of bleeding remains a constant concern for clinicians.

In 2015, the landscape improved with the global adoption of mechanical thrombectomy, a procedure where a catheter is threaded through the arteries to physically remove the clot. This technique extended the treatment window to 24 hours for some patients with large vessel occlusions. However, it is an invasive procedure that requires highly specialized equipment and personnel, limiting its availability to major stroke centers and leaving many patients in rural or underserved areas without access. BB-031, as a pharmacological agent, could potentially be administered in a much wider range of hospital settings.

The "Off-Switch": A Built-in Safety Net

Perhaps the most game-changing aspect of Basking's platform is not just BB-031, but its companion, BB-025. This investigational molecule is a rapid-acting reversal agent, an antidote designed specifically to bind to and neutralize BB-031 within minutes.

This "on-off switch" directly addresses the core fear that limits the use of current clot-busters: uncontrollable bleeding. If a patient receiving BB-031 develops a hemorrhage or requires emergency surgery, clinicians could theoretically administer BB-025 to immediately restore the body's normal clotting ability. This level of control is a paradigm shift, offering a safety net that could give doctors the confidence to treat patients who fall into a gray area of risk or who present outside the conventional time window.

The company is developing this safety agent in parallel with the main drug. A Phase 1 clinical study of BB-025 began dosing healthy volunteers in late 2025 to assess its safety and its ability to reverse the effects of BB-031, with plans to integrate it into the broader clinical program upon completion.

From Lab Bench to Bedside: The Path Forward

This promising preclinical data is not just a scientific curiosity; it's the foundation for a robust clinical program already underway. Basking Biosciences is advancing BB-031 through a Phase 2 study called the RAISE trial, which is enrolling patients with ischemic stroke who present within a much wider 24-hour window.

The trial is a two-part, placebo-controlled study designed to find the optimal dose and gather preliminary efficacy data. Part A was successfully completed in 2025, and the company is now enrolling approximately 180 patients for Part B across sites in North America and Australia, with a primary completion date estimated for mid-2027.

This clinical momentum is backed by significant financial and strategic confidence. The company has raised over $117 million to date, including a recent $55 million financing round led by top-tier investor ARCH Venture Partners. This funding is critical to navigating the expensive and complex path of late-stage drug development.

"This publication adds important mechanistic evidence to our program, and it is encouraging to see our approach validated in blood samples from stroke patients," said Julia C. Owens, Ph.D., chief executive officer of Basking Biosciences. "Findings like these strengthen our conviction as we advance BB-031 through our Phase 2 RAISE trial and work toward a treatment that could reach many stroke patients who do not currently receive acute treatment."

While the road from a Phase 2 trial to an approved medicine is long and fraught with uncertainty, the signal from Basking Biosciences is clear. By rethinking the fundamental biology of clot formation and building in a novel safety mechanism, BB-031 represents a tangible hope for shifting the unforgiving calculus of time and risk that has long defined the fight against stroke.